Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Recruiting

Phase 2

Brentuximab VedotinDosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT03587844

Conditions

Mycosis Fungoides

Lymphomatoid Papulosis

Sezary Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

brentuximab vedotin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2025-04-09.